171 related articles for article (PubMed ID: 31180724)
21. [Lercanidipine, a third generation calcium antagonist. Which advantages?].
Meier P; Burnier M
Rev Med Suisse; 2006 Sep; 2(78):2047-50, 2052-3. PubMed ID: 17019840
[TBL] [Abstract][Full Text] [Related]
22. Hypertension, possible vascular protection and lercanidipine.
Ram CV
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):783-8. PubMed ID: 17173495
[TBL] [Abstract][Full Text] [Related]
23. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
Tocci G; Palano F; Pagannone E; Chin D; Ferrucci A; Volpe M
Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):115-23. PubMed ID: 19210207
[TBL] [Abstract][Full Text] [Related]
24. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and JSH2009].
Ebina T; Kimura K; Umemura S
Clin Calcium; 2010 Jan; 20(1):16-22. PubMed ID: 20048429
[TBL] [Abstract][Full Text] [Related]
25. [Comparative analysis of the combined treatment efficacy of the Chernobyl accident clean-up workers with essential hypertension].
Habulavichene ZhM
Lik Sprava; 2012 Dec; (8):21-9. PubMed ID: 23786006
[TBL] [Abstract][Full Text] [Related]
26. [Kidney and hypertension--evidence based medicine].
Nakao N; Senou H; Kasuga H; Toriyama T; Kawahara H
Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1639-45. PubMed ID: 15384696
[No Abstract] [Full Text] [Related]
27. Renal protection with calcium antagonists: the role of lercanidipine.
Burnier M
Curr Med Res Opin; 2013 Dec; 29(12):1727-35. PubMed ID: 24069902
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
29. Fixed-dose lercanidipine/enalapril for hypertension.
Menne J; Haller H
Drugs Today (Barc); 2008 Apr; 44(4):261-70. PubMed ID: 18536784
[TBL] [Abstract][Full Text] [Related]
30. Lercanidipine : a review of its efficacy in the management of hypertension.
Bang LM; Chapman TM; Goa KL
Drugs; 2003; 63(22):2449-72. PubMed ID: 14609358
[TBL] [Abstract][Full Text] [Related]
31. A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities.
Iyer RP; Lindsey ML; Chilton RJ
J Clin Hypertens (Greenwich); 2013 Jul; 15(7):455-7. PubMed ID: 23815532
[No Abstract] [Full Text] [Related]
32. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension.
Ram CV
Am J Cardiol; 2002 Jan; 89(2):214-5. PubMed ID: 11792345
[No Abstract] [Full Text] [Related]
34. Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats.
Tomassoni D; Sabbatini M; Amenta F
J Cardiovasc Pharmacol; 2003 Apr; 41(4):544-52. PubMed ID: 12658055
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome.
Ghiadoni L; Bruno RM; Cartoni G; Stea F; Magagna A; Virdis A; Grassi D; Ferri C; Taddei S
Vascul Pharmacol; 2017 May; 92():16-21. PubMed ID: 26070528
[TBL] [Abstract][Full Text] [Related]
36. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Derosa G; Bonaventura A; Romano D; Bianchi L; Fogari E; D'Angelo A; Maffioli P
J Clin Pharm Ther; 2014 Jun; 39(3):277-85. PubMed ID: 24635387
[TBL] [Abstract][Full Text] [Related]
37. Dihydropyridine calcium channel blockers and renal disease.
Robles NR; Fici F; Grassi G
Hypertens Res; 2017 Jan; 40(1):21-28. PubMed ID: 27412800
[TBL] [Abstract][Full Text] [Related]
38. Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study.
Derosa G; Bonaventura A; Romano D; Bianchi L; Fogari E; D'Angelo A; Maffioli P
J Am Soc Hypertens; 2014 Jun; 8(6):422-8. PubMed ID: 24836352
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension.
Okura T; Miyoshi K; Irita J; Enomoto D; Jotoku M; Nagao T; Watanabe K; Matsuoka H; Ashihara T; Higaki J;
Clin Exp Hypertens; 2013; 35(8):563-9. PubMed ID: 23402476
[TBL] [Abstract][Full Text] [Related]
40. Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines.
Aronow WS
Expert Opin Pharmacother; 2016; 17(2):205-15. PubMed ID: 26373919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
